The artificial intelligence (AI) revolution continues to tout developing drugs faster and at lower cost, but are we there yet? On October 2nd, the FDA cleared an investigational new drug (IND) ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

(RTTNews) - Recursion (RXRX) said that the U.S. Food and Drug Administration has granted the company Fast Track designation for the investigation of REC-2282 for treatment of patients with NF2-mutated ...